In a first aspect, the present invention relates to a mutated Salmonella strain comprising mutations in flagellin II genes, like the fliF gene, in particular, in addition the aroA gene, the IpxR gene, the pagP gene, the pagL gene, the ydiV gene and optionally the eptA gene and further optionally, the arnT gene. In a further aspect, immunogenic compositions comprising said Salmonella strain are provided optionally together with a pharmaceutically accepted carrier, diluent or effluent. Moreover, a method for producing outer membrane vesicles of Salmonella is provided, said method comprises the steps of cultivating the Salmonella strain according to the present invention and isolating the outer membrane vesicles accordingly. The present invention provides the bacteria or the outer membrane vesicles (OMVs) obtainable by the methods according to the present invention and its use as a transport moiety or as an immunogenic composition, like a vaccine or immunotherapy platform espedaily for therapeutic treatment of cancer of tissue or blood.

The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

In certain embodiments, the present invention provides a recombinant Salmonella enterica serovar Typhi cell, vaccines and compositions, and methods of use thereof.

Adjuvants comprising chitosan cross-linked with, an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used, in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject.

The invention provides for an isolated antibody that specifically recognizes an epitope of the lipopolysaccharide (LPS) O3b-antigen structure of Klebsiella pneumoniae, which is a O3b-epitope incorporated in O3b-antigen comprising the structure of Formula (I), including one or more O3b-antigen mannose homopolymer repeating units, wherein MeP is methyl phosphate; and n is 0-50. The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

本发明涉及种用于预防或治疗由屋尘螨来源的过敏原引起的过敏性疾病的免疫调节剂。具体地而言，本发明提供种免疫调节药物组合物及其制备方法，所述免疫调节组合物包含含有北美屋尘螨或欧洲屋尘螨来源的过敏原的细菌的细胞外囊泡作为有效成分。

本发明公开了yfeCD基因敲除重组志贺氏菌的制备及应用。本发明提供了种构建重组菌的方法，为抑制或沉默福氏志贺氏菌基因组上的yfeCD基因表达，得到重组菌。本发明利用λRED同源重组的方法成功敲除了301中的yfeC/D基因，得到yfeC/D基因缺失株，并利用豚鼠角膜实验、III型分泌系统诱导分泌及小鼠肺竞争性侵袭三个毒力评价模型，初步断定其中yfeC/D基因缺失株的毒力有明显减弱，表明yfeC/D基因在志贺氏菌致病过程中有可能起到重要作用，得到的yfeC/D基因缺失株可以用作减毒疫苗的制备。

This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds. Typically the recombinant protein has a polypeptide of viral, fungal, or bacterial origin such as secreted effector proteins AvrA and YopJ. In certain embodiments, the disclosure relates to treating or preventing autoimmune diseases, cancer, or inflammatory diseases, or conditions such as inflammatory bowel disease (IBD).

Disclosed are devices, systems, and methods for the rapid and accurate detection of analytes, including Salmonella.

A human or humanized monoclonal IgG antibody (mAb) specifically recognizing the D-galactan-II antigen of Klebsiella pneumoniae O1 which is characterized by a bactericidal CDC activity, its method of production, medical and diagnostic use.

COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL PATHOGEN NUCLEIC ACID Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacterjejuni, and Campylobacter coli. Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL PATHOGEN NUCLEIC ACID Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacterjejuni, and Campylobacter coli. Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL PATHOGEN NUCLEIC ACID Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacterjejuni, and Campylobacter coli. Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL PATHOGEN NUCLEIC ACID Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacterjejuni, and Campylobacter coli. Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

The invention relates to bird feed comprising synthetic capsaicinoids for prohylactic use or treatment of salmonella infection.

Abstract Adjuvants comprising chitosan cross-linked with, an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used, in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject. c EE " *> * sO 0M V> + c QD~~ pl 1 P110OLUPS 1 A-8A03H WOJ4

A novel consortium used as potent vaccine for treating of enteric fever, comprised of isolated Outer Membrane Vesicles (OMVs) taken from two different strains of typhoidal Salmonella species.

The invention relates to a live vaccine for protection against enteric bacterial infection.

본 발명은 신규한 살모넬라 타이피뮤리움 균주 및 이를 포함하는 살모넬라 타이피뮤리움 감염증의 예방용 백신 조성물에 관한 것으로, 보다 구체적으로는 수탁번호 KCTC13198BP로 수탁된 살모넬라 타이피뮤리움 균주 ST26, 이를 포함하는 살모넬라 타이피뮤리움 감염증의 예방용 백신 조성물, 백신 조성물의 제조방법 및 상기 백신 조성물을 개체에 투여하여 살모넬라 타이피뮤리움 감염증을 예방하는 방법에 관한 것이다. 가금류로부터 분리된 본 발명의 신규한 살모넬라 타이피뮤리움 균주는 병원성이 높은 균주로서, 높은 안전성, 면역원성 및 방어능을 가지고 있는 바, 본 발명의 신규한 살모넬라 타이피뮤리움 균주를 포함하는 백신 조성물은 가금류 농가의 생산 안정성뿐만 아니라 인간에서의 살모넬라 타이피뮤리움 감염증 발생을 예방하는 데 유용하게 이용될 수 있다.

A human or humanized monoclonal IgG antibody (mAb) specifically recognizing the D-galactan-ll antigen of Klebsiella pneumoniae O1 which is characterized by a bactericidal CDC activity, its method of production, medical and diagnostic use.

The invention discloses a method for producing a single bacterial strain culture of Histomonas meleagridis (H. meleagridis), the method being characterised by the following steps: (a) providing a xenic culture of H. meleagridis comprising H. meleagridis cells with a wild type bacterial flora, (b) treating the xenic culture with a mixture of antibiotics thereby killing the wild type bacterial flora, (c) centrifuging and washing the H. meleagridis cells, (d) controlling effectiveness of step (b), (e) resuspending the washed H. meleagridis cells, (f) adding one or more single bacterial strain(s) to the resuspended H. meleagridis cells, and (g) culturing the one or more single bacterial strain(s) with the resuspended H. meleagridis cells so as to obtain a single bacterial strain culture of H. meleagridis. The invention further discloses a vaccine formulation consisting of a Histomonas component consisting of an attenuated culture of Histomonas meleagridis, a bacterial component consisting of one or more cultures of a single bacterial strain, and pharmaceutically acceptable non-biological formulation compounds.

The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections.

The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.

The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.

Resumen de: WO2018167290A1

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present invention relates to said attenuated strain of Salmonella for use in the treatment of cancer.